49results about How to "Provide survival rate" patented technology

The invention discloses a DSTN gene which can be used as a molecular marker of endometrial cancer diagnosis. A gene chip and a QPCR experiment are utilized to find that the DSTN gene and a coding protein thereof have remarkable difference in expression in a normal endometrial tissue and an endometrial cancer tissue, namely that the expression condition of the DSTN gene in the endometrial tissue can be detected to judge whether a subject suffers from endometrial cancer or has the risk of suffering from endometrial cancer or not. According to the correlation of the two, the invention develops a kit for diagnosing the endometrial cancer, and the kit is used for diagnosing the endometrial cancer by detecting the expression of the DSTN gene. The diagnosis kit can be used for early-stage diagnosis of diseases, and has a wide application prospect clinically. Besides, the invention further discloses the DSTN gene which can be used as a molecular target for treating the endometrial cancer, so that a foundation is provided for developing an endometrial cancer treatment drug.

The invention discloses a diagnosis and treatment target-IGSF6 gene for the multiple myeloma. By detecting the content of the IGSF6 gene and expression products of the IGSF6 gene in myeloid tissue of a testee, whether the testee suffers from the multiple myeloma or not can be judged or whether the testee bears a risk of suffering from the multiple myeloma or not can be diagnosed. In addition, by studying the proliferation, migration and invasion indexes of in-vitro cultured cells of the multiple myeloma, it is proved that the IGSF6 gene serves as a medicine target for treating the multiple myeloma.

The invention discloses a C16orf74 gene which can be taken as a biomarker for the renal clear cell carcinoma. The experiment proves that compared with normal nephridial tissues, the C16orf74 gene expression in renal clear cell carcinoma tissues is significantly improved. According to the research result, the C16orf74 gene can be applied to research and development of a kit used for diagnosing therenal clear cell carcinoma and also can be used for researching and developing medicines capable of inhibiting the C16orf74 gene expression, thereby achieving clinical prevention and treatment for therenal clear cell carcinoma.

The invention belongs to the field of biological medicines and discloses application of SYNM in preparation of tool for diagnosing or treating endometrial cancer. Experiments prove that the expressions of an SYNM gene in a normal endometrial tissue and an endometrial cancer tissue are significantly different, so that the SYNM can be used for developing products for diagnosing the endometrial cancer. The invention further discloses the SYNM gene which can be taken as a treatment target of the endometrial cancer. According to the research results of the invention, theoretical basis can be provided for clinicians to formulate individual-based treatment scheme, and a new drug target can be provided for the development of medicines for the endometrial cancer.

The invention discloses a genetic marker, namely, MS4A6A. The MS4A6A can be used for judging whether a subject has a risk of suffering from multiple myeloma or not or judging whether the subject suffers from the multiple myeloma. In additions, the MS4A6A can also be used for preparing drugs for treating the multiple myeloma. According to the MS4A6A, a novel diagnostic method is provided for diagnosing the multiple myeloma at the molecular level clinically, and meanwhile a novel drug target is provided for a gene therapy of the multiple myeloma.

The invention discloses a diagnosis and treatment target, namely TNS11 gene, for endometrial cancer. By detecting the contents of the TNS11 gene and expression products thereof, in the uterus tissue of a tested object, it can judge whether the tested object is affected by the endometrial cancer or not or it can diagnose whether the risk of the endometrial cancer exists in the tested object or not. In addition, by conducting researches on the proliferation and migration indexes of endometrial cancer cells which are cultured in vitro, it proves that the TNS11 gene can serve as a drug target for treating the endometrial cancer.

The invention belongs to the technical field of medicines, and discloses an ERI3 gene and new use of a code thereof. Studies prove that the ERI3 gene and encoded protein thereof not only can be taken as a molecular marker for diagnosing the multiple myeloma, but also can be used as a molecular target for treating the multiple myeloma. Based on the study results, the invention provides a new diagnosis method and treatment means for clinically.